





Article

# COVID-19 Outcomes in Kidney Transplant Recipients in a German Transplant Center

Michael Mikhailov <sup>1,2,\*</sup> , Klemens Budde <sup>1</sup> , Fabian Halleck <sup>1</sup> , Georgios Eleftheriadis <sup>1</sup> , Marcel G. Naik <sup>1</sup> ,  
Eva Schrezenmeier <sup>1</sup> , Friederike Bachmann <sup>1</sup> , Mira Choi <sup>1</sup> , Wiebke Duettmann <sup>1</sup> , Ellen von Hoerschelmann <sup>1</sup> ,  
Nadine Koch <sup>1</sup> , Lutz Liefeldt <sup>1</sup> , Christian Lücht <sup>1</sup> , Henriette Straub-Hohenbleicher <sup>1</sup> , Johannes Waiser <sup>1</sup> ,  
Ulrike Weber <sup>1</sup> , Bianca Zukunft <sup>1</sup>  and Bilgin Osmanodja <sup>1</sup> 

- <sup>1</sup> Department of Nephrology and Medical Intensive Care, Charité–Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany; klemens.budde@charite.de (K.B.); fabian.halleck@charite.de (F.H.); georgios.eleftheriadis@charite.de (G.E.); marcel.naik@charite.de (M.G.N.); eva-vanessa.schrezenmeier@charite.de (E.S.); friederike.bachmann@charite.de (F.B.); mira.choi@charite.de (M.C.); wiebke.duettmann@charite.de (W.D.); ellen.von-hoerschelmann@charite.de (E.v.H.); nadine.koch@charite.de (N.K.); lutz.liefeldt@charite.de (L.L.); christian.luecht@charite.de (C.L.); henriette.straub@charite.de (H.S.-H.); johannes.waiser@charite.de (J.W.); ulrike.weber@charite.de (U.W.); bianca.zukunft@charite.de (B.Z.); bilgin.osmanodja@charite.de (B.O.)
- <sup>2</sup> Clinic for Anaesthesiology and Intensive Care Medicine, Charité–Universitätsmedizin Berlin, Campus Benjamin Franklin, Hindenburgdamm 30, 12200 Berlin, Germany
- \* Correspondence: michael.mikhailov@charite.de

**Abstract:** Kidney transplant recipients (KTRs) show higher morbidity and mortality from COVID-19 than the general population and have an impaired response to vaccination. We analyzed COVID-19 incidence and clinical outcomes in a single-center cohort of approximately 2500 KTRs. Between 1 February 2020 and 1 July 2022, 578 KTRs were infected with SARS-CoV-2, with 25 (4%) recurrent infections. In total, 208 KTRs (36%) were hospitalized, and 39 (7%) died. Among vaccinated patients, infection with the Omicron variant had a mortality of 2%. Unvaccinated patients infected with the Omicron variant showed mortality (9% vs. 11%) and morbidity (hospitalization 52% vs. 54%, ICU admission 12% vs. 18%) comparable to the pre-Omicron era. Multivariable analysis revealed that being unvaccinated (OR = 2.15, 95% CI [1.38, 3.35]), infection in the pre-Omicron era (OR = 3.06, 95% CI [1.92, 4.87]), and higher patient age (OR = 1.04, 95% CI [1.03, 1.06]) are independent risk factors for COVID-19 hospitalization, whereas a steroid-free immunosuppressive regimen was found to reduce the risk of COVID-19 hospitalization (OR = 0.51, 95% CI [0.33, 0.79]). This suggests that both virological changes in the Omicron variant and vaccination reduce the risk for morbidity and mortality from COVID-19 in KTRs. Our data extend the knowledge from the general population to KTRs and provide important insights into outcomes during the Omicron era.

**Keywords:** kidney transplant recipients; immunosuppression; vaccination; SARS-CoV-2; COVID-19; Omicron



**Citation:** Mikhailov, M.; Budde, K.; Halleck, F.; Eleftheriadis, G.; Naik, M.G.; Schrezenmeier, E.; Bachmann, F.; Choi, M.; Duettmann, W.; von Hoerschelmann, E.; et al. COVID-19 Outcomes in Kidney Transplant Recipients in a German Transplant Center. *J. Clin. Med.* **2023**, *12*, 6103. <https://doi.org/10.3390/jcm12186103>

Academic Editor: Deborah Verran

Received: 10 August 2023

Revised: 2 September 2023

Accepted: 6 September 2023

Published: 21 September 2023



**Copyright:** © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

## 1. Introduction

The World Health Organization (WHO) proclaimed the Coronavirus disease 2019 (COVID-19) as a global pandemic in March 2020 [1]. The rapid emergence and subsequent dominance of new variants on a global scale have become characteristic features of SARS-CoV-2 [2]. The Omicron variant and the time period of its global dominance over other lineages, which can be defined as the Omicron era, relative to previous variants, was characterized by a less severe disease course, lower risk of hospitalization, ICU admission and death [3,4]. In the general population, this is due to a high rate of immunization by means of vaccination and repeated infection, less severe infections due to changes in the virus genome of the Omicron variant, the latter of which are, in part, counterbalanced by a

reduction in vaccine effectiveness due to immune escape by the Omicron variants [5]. More than 30 mutations in the spike gene (S) of the Omicron variant were detected in comparison to typically less than 15 in the Alpha and Delta variants [6]. It was assumed that Omicron's enhanced infectivity was due to increased replication in the bronchi, while its reduced severity was due to reduced penetration into deep lung tissue [7].

Due to their need for systemic immunosuppression, which may impair both cellular and humoral immune responses [8], kidney transplant recipients (KTRs), as well as other organ transplant recipients, show particularly high vulnerability in terms of COVID-19 [9]. KTRs are at high risk of developing a severe disease course with high rates of hospitalization, intensive care unit (ICU) admission, acute kidney injury (AKI), and COVID-19-related mortality [10,11]. COVID-19-related mortality of 14–23% was reported in KTRs [12–16], which was higher than that of the general population, where approximately 1% of patients infected with COVID-19 died until 20 October 2022 [17]. AKI in COVID-19 patients occurs frequently, and two mechanisms are discussed: direct tubular damage by the virus and systemic inflammation and ICU treatment [18,19].

Over time, morbidity and mortality from COVID-19 declined in the general population as well as in KTRs [20–23]. In KTRs, previous studies showed partially conflicting results regarding the outcomes of COVID-19 during the Omicron era: on the one side, decreased mortality was demonstrated uniformly; on the other side, variable rates of morbidity and hospitalization were reported [23–27]. Since Omicron variants showed increased immune escape, the protective effect of vaccination in KTRs during the Omicron era could be reduced.

Therefore, the objectives of the present study were to report data on COVID-19 disease course and outcomes, as well as to analyze the protective effect of the vaccination against SARS-CoV-2 in KTRs, depending on the predominant variant of concern (VoC).

## 2. Materials and Methods

### 2.1. Data Collection and Extraction

As a main source and interface for data collection, we used our proprietary electronic health record (EHR), TBase, which is fully integrated into the data infrastructure of Charité and enables convenient data acquisition from various data sources [28]. For the investigation of missing data, the EHR of Charité–Universitätsmedizin Berlin (SAP Deutschland SE & Co. KG, Walldorf, Germany) and additional internal databases and medical records were used.

Records of KTRs infected with SARS-CoV-2, as well as further data were identified and extracted using Microsoft Access 2016 (Version 16.0), applying queries with specific criteria, including positive SARS-CoV-2 PCR, positive Anti-SARS-CoV-2-(N)-Ag antibodies, ICD diagnosis U07.1 or U07.2, and medical notes indicating SARS-CoV-2 infection (e.g., positive SARS-CoV-2 rapid test performed by the patient or at a medical facility). The following data were extracted: patient age, sex, date of the last kidney transplantation, dates of infection and reinfection with SARS-CoV-2, dates of COVID-19-related hospital admission and discharge, ICU admission, incidence of acute kidney injury (AKI) as defined by KDIGO, date of death, number of vaccinations against SARS-CoV-2, and immunosuppressive medication at the time of infection with SARS-CoV-2.

Since no routine genetic sequencing was performed and, therefore, exact determination of the causative VoC was not feasible, we chose an indirect definition of VoC. In Germany, a clear predominance of Omicron cases occurred on 10 January 2022 [29]. Consequently, infection before that date was defined as the pre-Omicron era and afterward defined as the Omicron era. Over the course of the pandemic, the following vaccines were administered: BNT162b2 (Comirnaty, BioNTech/Pfizer, Mainz, Germany), mRNA-1273 (Spikevax, Moderna Biotech, Madrid, Spain), ChAdOx1-S (AZD1222, AstraZeneca, Södertälje, Sweden), or Ad26.COV2.S (Johnson & Johnson, Janssen, Beerse, Belgium) [30]. These vaccines were administered based on availability and not using a systematic approach. Therefore, various

combinations of vaccine regimens were ultimately administered. Patients who received at least one vaccine dose before infection were defined as being vaccinated.

## 2.2. Analytical Approach

Our primary endpoint was COVID-19-related hospitalization. Secondary endpoints were COVID-19-related death, AKI, and ICU admission.

The causal directed acyclic graphs (DAGs) in Figure A1 summarize our assumptions regarding the causal relationship of important measured and unmeasured variables, which are discussed in detail in Appendix A.1.

No imputation methods were used, and a complete case analysis was performed.


## 2.3. Statistical Analysis

All of the statistical analyses were performed using IBM SPSS Statistics (Version 28.0.1.0). First, we described the frequency of each outcome depending on the era of infection and vaccination status. Continuous variables were tested for normal distribution using a Shapiro–Wilk test and compared using binomial logistic regression analysis, the Mann–Whitney U test and Spearman’s correlation. Categorical variables were compared using the Chi-squared-test. Based on the assumptions above and the measured variables available, we included age, immunosuppression at the time of infection, time since transplantation, and era of infection as potential confounders when estimating the effect of vaccination on COVID-19 outcomes (hospitalization, COVID-19-related mortality, AKI, and ICU admission) by performing multinomial logistic regression. A *p*-value of 0.05 or less (two-tailed) was considered statistically significant.


The ethics committee of Charité–Universitätsmedizin Berlin approved this study (EA1/030/22).

## 3. Results

From approximately 2500 KTRs followed-up at our institution [31], 578 (23%) were identified to be infected with SARS-CoV-2 between 1 February 2020 and 1 July 2022. In total, 208 KTRs (36%) were hospitalized, and 39 (7%) died from COVID-19. Additionally, 10 patients died from other causes than COVID-19: infection (three patients), malignancy (two patients), sudden death (two patients), and hemorrhage (three patients). In total, 338 (58%) KTRs were vaccinated against SARS-CoV-2 prior to the infection, with a median number of three vaccination doses. The hospitalization rate for COVID-19 started to decrease at the end of the Delta wave in November and December 2021 and further decreased after the Omicron variant became dominant (Figures 1 and 2). Infection, hospitalization, and mortality trends, as well as demographics, course of disease and outcomes of COVID-19 are detailed in Figure 1, Figure 2 and Table 1, respectively.



**Figure 1.** Absolute numbers of COVID-19 infection, hospitalization, and mortality over time among KTR. Data are aggregated per month from February 2020 until June 2022. Omicron dominance occurred on 10 January 2022.



**Figure 2.** Hospitalization and mortality rate of COVID-19 among KTRs. Data are aggregated per month from February 2020 to June 2022. Omicron dominance occurred on 10 January 2022. During low incidence periods from May to August 2020 and June to August 2021, higher fluctuations in hospitalization rates were observed.

**Table 1.** Demographics of KTRs, COVID-19 disease course and outcomes.

KTRs infected with COVID-19, <i>n</i>	578
Reinfection, <i>n</i> (%)	25 (4)
Males, <i>n</i> (%)	355 (61)
Median age in years (IQR)	54.17 (19.24–85.57)
Median time post-KTx to COVID-19 in months (IQR)	101 (0–1463)
Vaccination before the infection, <i>n</i> (%)	338 (58)
<u>Immunosuppressive therapy at COVID-19 diagnosis</u>	
Mycophenolic acid, <i>n</i> (%)	481 (83)
Tacrolimus, <i>n</i> (%)	379 (66)
Cyclosporine, <i>n</i> (%)	110 (19)
Steroids, <i>n</i> (%)	373 (65)
Belatacept, <i>n</i> (%)	27 (5)
mTOR inhibitors, <i>n</i> (%)	14 (2)
Azathioprine, <i>n</i> (%)	18 (3)
Patients with missing data about IS, <i>n</i> (%)	35 (6)
<u>COVID-19 clinical course and management</u>	
Acute kidney injury	103 (18)
Hospitalization, <i>n</i> (%)	208 (36)
Median duration in days (IQR)	11 (1–123)
ICU admission, <i>n</i> (%)	73 (13)
<u>COVID-19 outcomes</u>	
Death, <i>n</i> (%) <sup>1</sup>	39 (7)

<sup>1</sup> COVID-19-related death; IQR—interquartile range; KTx—kidney transplantation; KTR—kidney transplant recipients; IS—immunosuppression.

At our center, 317 (55%) and 261 (45%) infections occurred in the pre-Omicron and Omicron era, respectively. Hospitalization rate decreased from 49% to 21% from the pre-Omicron to the Omicron era ( $p < 0.001$ ), and mortality decreased from 10% to 3% ( $p < 0.001$ ). Likewise, the proportion of patients admitted to the ICU decreased from 18% to 7% ( $p < 0.001$ ), and the number of patients with AKI decreased from 21% to 13% ( $p = 0.022$ ). The differences in disease course and outcomes between the pre-Omicron and Omicron eras are summarized in Table 2.

**Table 2.** Era-specific COVID-19 disease course and outcomes.

	Pre-Omicron <sup>1</sup>	Omicron <sup>2</sup>	<i>p</i>
KTRs infected with COVID-19, <i>n</i> (%)	317 (55)	261 (45)	
Reinfection, <i>n</i> (%)	23 (7)	2 (1)	
Vaccination before the infection, <i>n</i> (%)	110 (35)	228 (87)	
<b>COVID-19 clinical course and management</b>			
Acute kidney injury	68 (21)	35 (13)	0.022
Hospitalization, <i>n</i> (%)	154 (49)	54 (21)	<0.001
Median duration in days (IQR)	12 (1–123)	11 (1–103)	<0.001
ICU admission, <i>n</i> (%)	56 (18)	17 (7)	<0.001
Death, <i>n</i> (%) <sup>3</sup>	31 (10)	8 (3)	0.001

<sup>1</sup> before 10 January 2022; <sup>2</sup> from 10 January 2022; <sup>3</sup> COVID-19-related death; KTR—kidney transplant recipients; IQR—interquartile range.

Overall, 240 patients were not vaccinated before the infection with SARS-CoV-2, of which 205 (85%) were infected during the pre-Omicron and 35 (15%) during the Omicron era. Patients who were vaccinated before infection showed reduced reinfection rates (2% vs. 8%, *p* = 0.002), reduced hospitalization rates (24% vs. 53%, *p* < 0.001), reduced mortality rates (4% vs. 10%, *p* = 0.003), were less likely to be admitted to the ICU (9% vs. 17% *p* = 0.008), and were less likely to develop AKI (11% vs. 28%, *p* < 0.001) in comparison to unvaccinated patients.

Table 3 summarizes the data on COVID-19 disease course and outcomes depending on vaccination status. The protective effects of vaccination were more pronounced for the Omicron era than for the pre-Omicron era, which is summarized in Table 4. Unvaccinated patients infected in the Omicron era show mortality (9% vs. 11%) and morbidity (hospitalization 52% vs. 54%, ICU admission 12% vs. 18%) comparable to the pre-Omicron era, while vaccinated patients had improved outcomes, especially in the Omicron era with respect to mortality (2%) and morbidity (hospitalization, 16%; ICU admission, 6%). A logistic regression demonstrated that the number of vaccination doses was inversely correlated with mortality (OR 0.71, 95% CI [0.56–0.89]), hospitalization (OR 0.65, 95% CI [0.58–0.73]), ICU admission (OR 0.76, 95% CI [0.65–0.90]) and AKI (OR 0.73, 95% CI [0.63–0.84]). Figure 3 demonstrates the changes in hospitalization incidence with the increasing number of vaccination doses (applied before the first infection with SARS-CoV-2).

**Table 3.** COVID-19 disease course and outcomes of not vaccinated<sup>1</sup> and vaccinated<sup>1</sup> KTRs <sup>2</sup>.


	Not Vaccinated	Vaccinated	<i>p</i>
Total, <i>n</i>	240	338	
Reinfection, <i>n</i> (%)	18 (8)	7 (2)	0.002
Omicron <sup>3</sup> , <i>n</i> (%)	35 (15)	226 (67)	<0.001
<b>COVID-19 clinical course and management</b>			
Acute kidney injury	66 (28)	37 (11)	<0.001
Hospitalization, <i>n</i> (%)	128 (53)	80 (24)	<0.001
Median duration in days (IQR)	11 (1–123)	12 (1–123)	<0.001
ICU admission, <i>n</i> (%)	41 (17)	32 (9)	0.008
Death, <i>n</i> (%) <sup>4</sup>	25 (10)	14 (4)	0.003

<sup>1</sup> prior to the SARS-CoV-2 infection; <sup>2</sup> kidney transplant recipients <sup>3</sup> from 10 January 2022; <sup>4</sup> COVID-19-related death. KTRs—kidney transplant recipients; ICU—intensive care unit; IQR—interquartile range.

**Table 4.** Era- and vaccination-specific COVID-19 disease outcomes.

	Pre-Omicron <sup>1</sup>		Omicron <sup>2</sup>	
	Vaccinated	Not Vaccinated	Vaccinated	Not Vaccinated
KTRs infected with COVID-19, <i>n</i> (%) <sup>3</sup>	110 (35)	207 (65)	228 (87)	33 (13)
Reinfection, <i>n</i> (%)	5 (5)	18 (9)	2 (1)	0 (0)
<u>COVID-19 outcomes</u>				
Acute kidney injury	16 (15)	52 (25)	21 (9)	14 (42)
Hospitalization, <i>n</i> (%)	43 (39)	111 (54)	37 (16)	17 (52)
Duration in days (IQR)	14 (1–123)	11 (1–123)	11 (1–86)	12 (3–103)
ICU admission, <i>n</i> (%)	19 (17)	37 (18)	13 (6)	4 (12)
Death, <i>n</i> (%) <sup>4</sup>	9 (8)	22 (11)	5 (2)	3 (9)


<sup>1</sup> before 10 January 2022; <sup>2</sup> from 10 January 2022; <sup>3</sup> of all pre-Omicron/Omicron patients; <sup>4</sup> COVID-19-related death. KTRs—kidney transplant recipients; IQR—interquartile range.



**Figure 3.** Distribution of hospitalization incidence depending on the number of vaccination doses.

To estimate the effect of vaccination on COVID-19-related outcomes, we adjusted for potential confounding due to era of infection, age, immunosuppression, and time since transplantation (cf. Figure A1 and Item A1) in the multivariable regression. We found that being unvaccinated (OR = 2.15, 95% CI [1.38, 3.35]), infection in the pre-Omicron era (OR = 3.06, 95% CI [1.92, 4.87]) and higher patient age (OR = 1.04, 95% CI [1.03, 1.06]) were independent risk factors for COVID-19 hospitalization. For COVID-19-related death, only infection in the pre-Omicron era (OR = 3.08, 95% CI [1.14, 8.33]) and higher patient age (OR = 1.10, 95% CI [1.06, 1.14]) were independent risk factors. Being unvaccinated (OR = 2.72, 95% CI [1.55, 4.77]) and higher patient age (OR = 1.03, 95% CI [1.02, 1.05]) were independent risk factors for COVID-19-related acute kidney injury. For ICU admission, infection in the pre-Omicron era (OR = 3.22, 95% CI [1.63, 6.37]) and higher patient age (OR = 1.06, 95% CI [1.03, 1.08]) were independent risk factors. A steroid-free immunosuppressive regimen was found to be a protective factor both against hospitalization for COVID-19 (OR = 0.51, 95% CI [0.33, 0.79]), COVID-19-related acute kidney injury (OR = 0.45, 95% CI [0.26, 0.80]) and ICU admission (OR = 0.43, 95% CI [0.22, 0.83]) (Figure 4). Other immunosuppressive agents (mycophenolic acid, tacrolimus, cyclosporine, belata-

cept, mTOR inhibitors, and azathioprine) were not significantly associated with COVID-19 mortality or morbidity.



**Figure 4.** Forest plot summarizing the odds ratios of steroid intake, vaccination status, era of infection, time since transplantation, and patient age for hospitalization (A), COVID-19-related death (B), acute kidney injury (C) and ICU admission (D) in KTRs with COVID-19 from February 2020 to June 2022.

We furthermore analyzed the rejection rates in both eras. In the pre-Omicron era, 88 rejection episodes occurred over the 1.94-year observation period, while in the Omicron era, 28 rejection episodes occurred over the 0.47-year observation period. Based on the population size of 2500 patients, the rejection rates were 1.81/100 patient-years in the pre-Omicron era and 2.38/100 patient-years in the Omicron era. At the same time, a small increase in biopsies occurred (5.5 biopsies/100 patient-years in the pre-Omicron era vs. 7.2 biopsies/100 patient-years in the Omicron era).

#### 4. Discussion

In the present article, we show that hospitalization rate and COVID-19-related mortality and morbidity in KTRs with COVID-19 decreased since the beginning of the pandemic, but especially after the Omicron variant became dominant, and a higher proportion of patients were vaccinated. We further show that both infection in the pre-Omicron era and being unvaccinated are independent risk factors for COVID-19-related hospitalization in KTRs. Other factors affecting disease severity, assessed in terms of hospitalization and COVID-19-related death, included patient age and steroid intake. Other immunosuppressive agents did not affect disease severity in our analysis.

Additionally, the number of vaccinations was inversely correlated with morbidity and mortality, further underlining the protective effect of vaccination in KTRs.

These findings are in line with observations in the general population, where both vaccination and Omicron variant reduced the risk of severe COVID-19, independently [5]. Within our cohort, we could also confirm that patient age and steroid intake pose risk factors for severe COVID-19, which has been described before in the general population as well as in other cohorts of KTRs [24,32–34].

Our findings highlight that mortality and morbidity in unvaccinated KTRs remain unchanged after Omicron dominance, underlining the ongoing need for vaccination or alternative immunization strategies in this vulnerable group of patients [35]. Vaccination significantly reduced the rate of hospitalization and disease-specific morbidity and mortality during the Omicron era.

The reinfection rate in patients with COVID-19 has not been studied before, probably due to the rather low frequency of reinfections and small cohorts. We found the reinfection rate to be strongly associated with vaccination status, with the majority of reinfections occurring in unvaccinated patients, which is in line with the existing literature for the general population [36,37]. The overall infection rate in KTRs was smaller (23%) than for the general population, where approximately 32% were infected until 17 June 2022, according to [38]. Since the estimated number of undetected cases is probably higher in the general population, where testing is less likely to be performed in mild cases, we hypothesize that KTRs are more cautious and avoid potential infections more successfully than the general population.

Rejection rates were slightly increased in the Omicron era in comparison to the pre-Omicron era, which is mostly explained by an increase in biopsies performed. This suggests that virological changes did not influence rejection rates in KTRs but that admission policies due to institutional restrictions and patient preferences were more important.

#### *Strengths and Limitations*

This is one of the first studies to analyze disease outcomes in KTRs during the Omicron era. The incidence of COVID-19 and clinical outcomes after infection were assessed in a large cohort of closely monitored KTRs with granular data on outcome and vaccination status. Since most KTRs with COVID-19 were followed-up at our institution using a telemedicine approach and were hospitalized at our center if necessary, the ground truth of the underlying data on hospitalization, ICU admission, AKI, and mortality is high [39].

The major limitation is that therapeutic measures, such as treatment with monoclonal antibodies or antiviral therapies, like remdesivir, have not been included into our analysis [40,41]. Consequently, the decrease in disease severity is not solely explained by vaccination and virological changes but in part due to the increased availability and use of therapeutic agents. Another limitation concerns the power of this study. Especially with respect to mortality, the event rate was rather low ( $n = 39$ ), which reduces the reliability of the results from multivariable analysis for this endpoint. Since we only analyzed the influence of single immunosuppressive agents on COVID-19 disease severity, we could not exclude that certain combinations of immunosuppressive agents may influence the risk. However, since most patients received a calcineurin inhibitor and mycophenolic acid with or without steroids as maintenance immunosuppression, the reliability of analyses for the other immunosuppressive agents is reduced due to the low patient count.

## 5. Conclusions

Disease severity and mortality from COVID-19 are substantially reduced in vaccinated KTRs infected during the Omicron era. Unvaccinated KTRs show high mortality and morbidity independent of the causative variant.

**Author Contributions:** Data analysis, paper concept, writing of the paper, M.M.; paper concept, writing of the paper, patient treatment, data entry, B.O.; paper concept, patient treatment, data entry, reviewing the final manuscript, K.B. and F.H.; patient treatment, data entry, reviewing the final manuscript, G.E., M.G.N., E.S., F.B., M.C., W.D., E.v.H., N.K., L.L., C.L., H.S.-H., J.W., U.W. and B.Z. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research received no external funding.

**Institutional Review Board Statement:** The ethics committee of Charité–Universitätsmedizin Berlin approved this study (EA1/030/22).




**Informed Consent Statement:** Patient consent was waived due to the retrospective nature of this analysis in accordance with the German legislation and was approved by the ethics committee of harité–Universitätsmedizin Berlin.

**Data Availability Statement:** Not applicable.

**Conflicts of Interest:** The authors declare no conflict of interest.

**Appendix A**



**Figure A1.** Causal diagram summarizing the assumptions underlying the analysis. Yellow—unmeasured variables; green—measured variables; \* unmeasured mediators. Adjusting for the era of infection eliminates confounding that is caused by the time of infection on vaccination status. Among “other factors”, some variables such as age, immunosuppressive medication, and transplant age were measured, and could be adjusted for during multivariable regression to eliminate potential confounding. Other variables, such as estimated glomerular filtration rate, are unmeasured and remain a potential source of confounding. COVID-19-specific therapies were not assessed, but since they are not a cause for vaccination status, adjustment is not necessary. Assessment of the unmeasured mediators “virological changes” or “vaccine efficacy” is not necessary to estimate the effect of vaccination on our outcomes either.

*Appendix A.1. Explanation of the Causal Assumptions*

Of greatest importance is the confounding due to “infection after 10 January 2022”, which is equivalent to the definition of Omicron vs. pre-Omicron era. This variable influences the vaccination status (at the time of infection) since the likelihood of being vaccinated increased over time, and it influences the causative VoC, which through an unmeasured mediator (virological changes), is suspected to influence our outcomes. To a lesser extent, it influences the availability of COVID-19-specific therapies. While most of these therapies were approved before that date (remdesivir on 2 July 2020, and casirivmab/indevimab on 11 November 2021), the use of monoclonal antibodies became more common before and shortly after Omicron dominance, especially with the availability of sotrovimab and

tixagevimab/cilgavimab. Therefore, we need to adjust for the era of infection when determining the effect of vaccination on the outcomes.

Whether other factors, such as patient age, time since transplantation, and immunosuppressive medication at the time of infection influence the vaccination status, is debatable. On the one hand, one could argue that all patients, independent of these factors, should be vaccinated and that there is no causal relationship. Otherwise, it is at least conceivable that, e.g., patients with esoteric beliefs are more likely to take less immunosuppressive medication and also be unvaccinated. Under such circumstances, adjusting for the immunosuppressive medication could eliminate some of the confounding caused by an unmeasured variable, such as “esoteric beliefs”. Since we do not cause selection bias by adjusting for variables such as age, time since transplantation and immunosuppressive medication, and they are likely to influence our outcomes, we decided to adjust for these variables in the multivariable regression analysis. Furthermore, there are unmeasured variables, such as estimated glomerular filtration rate (eGFR), which we did not adjust for and which remain a potential cause for confounding [30,42].

## References

1. Navari, Y.; Bagheri, A.B.; Rezayat, A.A.; SeyedAlinaghi, S.; Najafi, S.; Barzegary, A.; Asadollahi-Amin, A. Mortality risk factors in kidney-transplanted patients with COVID-19: A systematic review and regression analysis. *Health Sci. Rep.* **2021**, *4*, e427. [CrossRef]
2. Kun, Á.; Hubai, A.G.; Král, A.; Mokos, J.; Mikulecz, B.Á.; Radványi, Á. Do pathogens always evolve to be less virulent? The virulence–transmission trade-off in light of the COVID-19 pandemic. *Biol. Futur.* **2023**, *74*, 69–80. [CrossRef]
3. Mendiola-Pastrana, I.R.; López-Ortiz, E.; Río de la Loza-Zamora, J.G.; González, J.; Gómez-García, A.; López-Ortiz, G. SARS-CoV-2 Variants and Clinical Outcomes: A Systematic Review. *Life* **2022**, *12*, 21. [CrossRef]
4. Shin, D.H.; Smith, D.M.; Choi, J.Y. SARS-CoV-2 Omicron Variant of Concern: Everything You Wanted to Know about Omicron but Were Afraid to Ask. *Yonsei Med. J.* **2022**, *63*, 977–983. [CrossRef]
5. Nyberg, T.; Ferguson, N.M.; Nash, S.G.; Webster, H.H.; Flaxman, S.; Andrews, N.; Thelwall, S. Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: A cohort study. *Lancet* **2022**, *399*, 1303–1312. [CrossRef]
6. Ou, J.; Lan, W.; Wu, X.; Zhao, T.; Duan, B.; Yang, P.; Zhang, Q. Tracking SARS-CoV-2 Omicron diverse spike gene mutations identifies multiple inter-variant recombination events. *Signal Transduct. Target. Ther.* **2022**, *7*, 9. [CrossRef]
7. Hui, K.P.; Ho, J.C.; Cheung, M.C.; Ng, K.C.; Ching, R.H.; Lai, K.L.; Chan, M.C. SARS-CoV-2 Omicron variant replication in human bronchus and lung ex vivo. *Nature* **2022**, *603*, 715–720. [CrossRef]
8. Schrezenmeier, E.; Rincon-Arevalo, H.; Jens, A.; Stefanski, A.L.; Hammett, C.; Osmanodja, B.; Budde, K. Temporary antimetabolite treatment hold boosts SARS-CoV-2 vaccination-specific humoral and cellular immunity in kidney transplant recipients. *JCI Insight* **2022**, *7*, 11. [CrossRef]
9. Ferreira, V.H.; Solera, J.T.; Hu, Q.; Hall, V.G.; Arbol, B.G.; Hardy, W.R.; Samson, R.; Marinelli, T.; Ierullo, M.; Virk, A.K.; et al. Homotypic and heterotypic immune responses to Omicron variant in immunocompromised patients in diverse clinical settings. *Nat. Commun.* **2022**, *13*, 4489. [CrossRef]
10. Goffin, E.; Candellier, A.; Vart, P.; Noordzij, M.; Arnol, M.; Covic, A.; Lentini, P.; Malik, S.; Reichert, L.J.; Sever, M.S.; et al. COVID-19-related mortality in kidney transplant and haemodialysis patients: A comparative, prospective registry-based study. *Nephrol. Dial. Transplant.* **2021**, *36*, 2094–2105. [CrossRef]
11. Solera, J.T.; Árbol, B.G.; Alshahrani, A.; Bahinskaya, I.; Marks, N.; Humar, A.; Kumar, D. Impact of Vaccination and Early Monoclonal Antibody Therapy on Coronavirus Disease 2019 (COVID-19) Outcomes in Organ Transplant Recipients During the Omicron Wave. *Clin. Infect. Dis.* **2022**, *75*, 2193–2200. [CrossRef]
12. Kremer, D.; Pieters, T.T.; Verhaar, M.C.; Berger, S.P.; Bakker, S.J.; van Zuilen, A.D.; Joles, J.A.; Vernooij, R.W.; van Balkom, B.W. A systematic review and meta-analysis of COVID-19 in kidney transplant recipients: Lessons to be learned. *Am. J. Transplant.* **2021**, *21*, 3936–3945. [CrossRef]
13. Chen, J.-J.; Kuo, G.; Lee, T.H.; Yang, H.-Y.; Wu, H.H.; Tu, K.-H.; Tian, Y.-C. Incidence of Mortality, Acute Kidney Injury and Graft Loss in Adult Kidney Transplant Recipients with Coronavirus Disease 2019: Systematic Review and Meta-Analysis. *J. Clin. Med.* **2021**, *10*, 5162. [CrossRef]
14. Opsomer, R.; Kuypers, D. COVID-19 and solid organ transplantation: Finding the right balance. *Transplant. Rev.* **2022**, *36*, 100710. [CrossRef]
15. Devresse, A.; De Greef, J.; Yombi, J.C.; Belkhir, L.; Goffin, E.; Kanaan, N. Immunosuppression and SARS-CoV-2 Infection in Kidney Transplant Recipients. *Transplant. Direct* **2022**, *8*, 9. [CrossRef]
16. Nimmo, A.M.; Gardiner, D.M.; Ushiro-Lumb, I.M.; Ravanan, R.M.; Forsythe, J.L.R.M. The Global Impact of COVID-19 on Solid Organ Transplantation: Two Years Into a Pandemic. *Transplantation* **2022**, *106*, 1312–1329. [CrossRef]
17. WHO Coronavirus (COVID-19) Dashboard. Available online: <https://covid19.who.int/> (accessed on 25 February 2023).

18. Jafari-Oori, M.; Fiorentino, M.; Castellano, G.; Ebadi, A.; Rahimi-Bashar, F.; Guest, P.C.; Vahedian-Azimi, A.; Sahebkar, A. Acute Kidney Injury and COVID-19: A Scoping Review and Meta-Analysis. In *Clinical, Biological and Molecular Aspects of COVID-19*; Guest, P.C., Ed.; Springer International Publishing Ag: Cham, Switzerland, 2021; pp. 309–324. [\[CrossRef\]](#)
19. Fiorentino, M.; Bagagli, F.; Deleonardis, A.; Stasi, A.; Franzin, R.; Conserva, F.; Infante, B.; Stallone, G.; Pontrelli, P.; Gesualdo, L. Acute Kidney Injury in Kidney Transplant Patients in Intensive Care Unit: From Pathogenesis to Clinical Management. *Biomedicines* **2023**, *11*, 1474. [\[CrossRef\]](#)
20. Dennler, U.; Geisler, F.; Spinner, C.D. Declining COVID-19 morbidity and case fatality in Germany: The pandemic end? *Infection* **2022**, *50*, 1625–1626. [\[CrossRef\]](#)
21. Cochran, W.C.; Shah, P.; Barker, L.C.; Langlee, J.C.; Freed, K.C.; Boyer, L.C.; Anderson, R.S.; Belden, M.C.; Bannon, J.M.; Kates, O.S.M.; et al. COVID-19 Clinical Outcomes in Solid Organ Transplant Recipients During the Omicron Surge. *Transplantation* **2022**, *106*, e346–e347. [\[CrossRef\]](#)
22. Geetha, D.; Kronbichler, A.; Rutter, M.; Bajpai, D.; Menez, S.; Weissenbacher, A.; Anand, S.; Lin, E.; Carlson, N.; Sozio, S.; et al. Impact of the COVID-19 pandemic on the kidney community: Lessons learned and future directions. *Nat. Rev. Nephrol.* **2022**, *18*, 724–737. [\[CrossRef\]](#)
23. Papadimitriou-Olivgeris, M.; Cipriano, A.; Guggisberg, N.; Kroemer, M.; Tschopp, J.; Manuel, O.; Golshayan, D. Outcome of COVID-19 in Kidney Transplant Recipients Through the SARS-CoV-2 Variants Eras: Role of Anti-SARS-CoV-2 Monoclonal Antibodies. *Transpl. Int.* **2022**, *35*, 9. [\[CrossRef\]](#) [\[PubMed\]](#)
24. Anjan, S.; Khatri, A.; Viotti, J.B.; Cheung, T.; Garcia LA, C.; Simkins, J.; Natori, Y. Is the Omicron variant truly less virulent in solid organ transplant recipients? *Transpl. Infect. Dis.* **2022**, *24*, e13923. [\[CrossRef\]](#)
25. Banjongjit, A.; Lertussavavivat, T.; Paitoonpong, L.; Puthcharoen, O.; Vanichanan, J.; Wattanatorn, S.; Tungsanga, K.; Eiam-Ong, S.; Avihingsanon, Y.; Tungsanga, S.; et al. The Predictors for Severe SARS-CoV-2 Omicron (B.1.1.529) and Pre-Omicron Variants Infection Among Kidney Transplant Recipients. *Transplantation* **2022**, *106*, e520–e521. [\[CrossRef\]](#)
26. Wong, G.; Rowlandson, M.; Sabanayagam, D.; Ginn, A.N.; Kable, K.; Sciberras, F.; Kok, J. COVID-19 Infection with the Omicron SARS-CoV-2 Variant in a Cohort of Kidney and Kidney Pancreas Transplant Recipients: Clinical Features, Risk Factors, and Outcomes. *Transplantation* **2022**, *106*, 1860–1866. [\[CrossRef\]](#) [\[PubMed\]](#)
27. Rodríguez-Cubillo, B.; de la Higuera MA, M.; Pérez-Flores, I.; Romero, N.C.; Aiffil, A.S.; Vilela, A.A.; Sanchez-Fructuoso, A.I. Clinical Effectiveness of SARS-CoV-2 Vaccination in Renal Transplant Recipients. Antibody Levels Impact in Pneumonia and Death. *Transplantation* **2022**, *106*, E476–E487. [\[CrossRef\]](#) [\[PubMed\]](#)
28. Schmidt, D.; Osmanodja, B.; Pfefferkorn, M.; Graf, V.; Raschke, D.; Duettmann, W.; Budde, K. TBase—An Integrated Electronic Health Record and Research Database for Kidney Transplant Recipients. *Jove-J. Vis. Exp.* **2021**, e61971. [\[CrossRef\]](#)
29. Robert-Koch-Institut. Übersicht zu Omikron-Fällen in Deutschland 2022. Available online: [https://www.rki.de/DE/Content/InfAZ/N/Neuartiges\\_Coronavirus/Situationsberichte/Omikron-Faelle/Omikron-Faelle.html](https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Situationsberichte/Omikron-Faelle/Omikron-Faelle.html) (accessed on 21 October 2022).
30. Osmanodja, B.; Ronicke, S.; Budde, K.; Jens, A.; Hammett, C.; Koch, N.; Schrezenmeier, E. Serological Response to Three, Four and Five Doses of SARS-CoV-2 Vaccine in Kidney Transplant Re-cipients. *J. Clin. Med.* **2022**, *11*, 2565. [\[CrossRef\]](#)
31. Osmanodja, B.; Mayrdorfer, M.; Halleck, F.; Choi, M.; Budde, K. Undoubtedly, kidney transplant recipients have a higher mortality due to COVID-19 disease compared to the general population. *Transpl. Int.* **2021**, *34*, 769–771. [\[CrossRef\]](#)
32. Veeranki, V.; Prasad, N.; Meyyappan, J.; Bhadauria, D.; Behera, M.R.; Kushwaha, R.; Kaul, A. The adverse effects of high-dose corticosteroid on infectious and non-infectious sequelae in renal transplant recipients with coronavirus disease-19 in India. *Transpl. Infect. Dis.* **2022**, *24*, e13908. [\[CrossRef\]](#)
33. Gérard, A.O.; Barbosa, S.; Anglicheau, D.; Couzi, L.; Hazzan, M.; Thauinat, O.; Blancho, G.; Caillard, S.; Sicard, A.; French SOT COVID Registry. Association between Maintenance Immunosuppressive Regimens and COVID-19 Mortality in Kidney Transplant Recipients. *Transplantation* **2022**, *106*, 2063–2067. [\[CrossRef\]](#)
34. Requião-Moura, L.R.; de Sandes-Freitas, T.V.; Viana, L.A.; Cristelli, M.P.; de Andrade, L.G.M.; Garcia, V.D.; de Oliveira, C.M.C.; Esmeraldo, R.d.M.; Filho, M.A.; Pacheco-Silva, A.; et al. High mortality among kidney transplant recipients diagnosed with coronavirus disease 2019: Results from the Brazilian multicenter cohort study. *PLoS ONE* **2021**, *16*, e0254822. [\[CrossRef\]](#) [\[PubMed\]](#)
35. Levin, M.J.; Ustianowski, A.; De Wit, S.; Launay, O.; Avila, M.; Templeton, A.; Yuan, Y.; Seegobin, S.; Ellery, A.; Levinson, D.J.; et al. Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for Prevention of COVID-19. *N. Engl. J. Med.* **2022**, *386*, 2188–2200. [\[CrossRef\]](#) [\[PubMed\]](#)
36. Flacco, M.E.; Acuti Martellucci, C.; Baccolini, V.; De Vito, C.; Renzi, E.; Villari, P.; Manzoli, L. COVID-19 vaccines reduce the risk of SARS-CoV-2 reinfection and hospitalization: Meta-analysis. *Front. Med.* **2022**, *9*, 3313. [\[CrossRef\]](#) [\[PubMed\]](#)
37. Flacco, M.E.; Acuti Martellucci, C.; Baccolini, V.; De Vito, C.; Renzi, E.; Villari, P.; Manzoli, L. Risk of reinfection and disease after SARS-CoV-2 primary infection: Meta-analysis. *Eur. J. Clin. Investig.* **2022**, *52*, e13845. [\[CrossRef\]](#)
38. Robert-Koch-Institut. Gesamtübersicht der pro Tag ans RKI übermittelten Fälle und Todesfälle. 2022. Available online: [https://www.rki.de/DE/Content/InfAZ/N/Neuartiges\\_Coronavirus/Daten/Fallzahlen\\_Gesamtuebersicht.html](https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Daten/Fallzahlen_Gesamtuebersicht.html) (accessed on 19 October 2022).
39. Duettmann, W.; Naik, M.G.; Schmidt, D.; Pfefferkorn, M.; Kurz, M.; Graf, V.; Budde, K. Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform. *Jove-J. Vis. Exp.* **2021**, e61899. [\[CrossRef\]](#)

40. Holland, T.L.; Ginde, A.A.; Paredes, R.; Murray, T.A.; Engen, N.; Grandits, G.; Lundgren, J.D. Tixagevimab-cilgavimab for treatment of patients hospitalised with COVID-19: A randomised, double-blind, phase 3 trial. *Lancet Respir. Med.* **2022**, *10*, 972–984. [[CrossRef](#)]
41. Beigel, J.H.; Tomashek, K.M.; Dodd, L.E.; Mehta, A.K.; Zingman, B.S.; Kalil, A.C.; Hohmann, E.; Chu, H.Y.; Luetkemeyer, A.; Kline, S.; et al. Remdesivir for the Treatment of COVID-19—Final Report. *N. Engl. J. Med.* **2020**, *383*, 1813–1826. [[CrossRef](#)]
42. Seidel, A.; Jahrsdörfer, B.; Körper, S.; Albers, D.; Maltitz, P.V.; Müller, R.; Schrezenmeier, H. SARS-CoV-2 vaccination of convalescents boosts neutralization capacity against SARS-CoV-2 Delta and Omicron that can be predicted by anti-S antibody concentrations in serological assays. *medRxiv* **2022**. [[CrossRef](#)]

**Disclaimer/Publisher’s Note:** The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.